Monitoring Agency Report

INDGN/SE/2026-27/36 30 July 2026 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Madam, Subject: Intimation of Monitoring Agency Report for the quarter ended June 30, 2026 Pursuant to Regulation 32 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 41 of Securities Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find attached Monitoring Agency Report for the quarter ended June 30, 2026, issued by Care Edge Ratings, Monitoring Agency, appointed to monitor the utilisation of proceeds of the Public Issue (IPO) of the Company. This will also be posted on the company’s website at: https://www.indegene.com/ We request you to kindly take the same on record. Thanking You Yours Sincerely, For Indegene Limited Srishti Ramesh Kaushik Company Secretary and Compliance Officer Encl: A/a Indegene Limited Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru- 560 045, Karnataka, India Phone: +91 80 4674 4567, +91 80 4644 7777 compliance.officer@indegene.com www.indegene.com CIN: L73100KA1998PLC102040 Monitoring Agency Report No. CARE/HO/GEN/2026-27/1105 The Board of Directors Indegene Limited Aspen Block G4, 3rd Floor, Manyata Embassy Business Park, Outer Ring Road, Nagawara, Bengaluru – 560 045, Karnataka, India. July 29, 2026 Dear Sir/Ma’am, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the Initial Public Offering (IPO) of Indegene Limited (“the Company”) We write in our capacity of Monitoring Agency for the IPO for the amount aggregating to Rs. 760.00 crores of the Company and refer to our duties cast under Regulation 41 of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations. In this connection, we are enclosing the Monitoring Agency Report for the quarter ended June 30, 2026, as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated April 25, 2024. Request you to kindly take the same on records. Thanking you, Yours faithfully, Darshan Shah Associate Director Darshan.shah@careedge.in Monitoring Agency Report Report of the Monitoring Agency Name of the issuer: Indegene Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: CARE Ratings Limited (a) Deviation from the objects: NIL (b) Range of Deviation: Not Applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name of the Authorized Signatory: Darshan Shah Designation of Authorized person/Signing Authority: Associate Director ft Monitoring Agency Report 1) Issuer Details: Name of the issuer : Indegene Limited Name of the promoter : The company does not have an identifiable promoter in terms of the SEBI ICDR Regulations and the Companies Act. Industry/sector to which it belongs : Healthcare Services - Healthcare Research, Analytics & Technology 2) Issue Details Issue Period : May 06, 2024, to May 08, 2024 Type of issue (public/rights) : Initial Public Offer (IPO) Type of specified securities : Equity Shares IPO Grading, if any : Not Applicable Issue size (in crore) : Rs. 760.00 crores 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information / certifications Comments of the Comments of the Particulars Reply considered by Monitoring Agency for Board of Monitoring Agency preparation of report Directors Utilization of gross proceeds in the reporting quarter is towards the objects specified in prospect and the revised object as approved by shareholders via special resolution (Refer Note 1 below the table). Prospectus, Bank Statement, Management Whether all utilization is as per the disclosures in the Offer Certificate, Management Authorization There has been delay in utilization of No comment Document? Letter, Special Resolution*, Board Resolution the proceeds towards the object received and Invoices. ‘Funding the capital expenditure requirements of the company and one of their material subsidiaries, Indegene Inc.’ for which no approval was taken for timeline extension (refer to table 4 (iv) - Delay in implementation of the object(s)). ft Monitoring Agency Report Source of information / certifications Comments of the Comments of the Particulars Reply considered by Monitoring Agency for Board of Monitoring Agency preparation of report Directors Whether shareholder approval has been obtained in case of No comment material deviations# from expenditures disclosed in the Offer Yes Special Resolution* Refer Note 1 below the table received Document? Whether the means of finance for the disclosed objects of the Not No comment Management Certificate - issue have changed? Applicable received There was a deviation mentioned in the MA report for Q3FY25 for Is there any major deviation observed over the earlier monitoring No comment No Previous Monitoring Agency reports exceeding GCP utilization beyond the agency reports? received stipulated limit which was rectified in subsequent quarter of Q4FY25. Whether all Government/statutory approvals related to the Not No comment Prospectus and Management Certificate - object(s) have been obtained? Applicable received Whether all arrangements pertaining to technical Not No comment Management certificate - assistance/collaboration are in operation? Applicable received There has been delay in deployment of funds for the Object namely ‘Funding the capital expenditure Are there any favorable/unfavorable events affecting the viability No comment Yes Prospectus, Bank Statement requirements of the company and of these object(s)? received one of their material subsidiaries, Indegene Inc.’ for the milestone ending as on March 31, 2026. Is there any other relevan [Showing first 8,000 characters — download PDF for full document]